Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

Lynparza tablets are indicated in combination with bevacizumab for the maintenance treatment of patients with advanced HRD-positive ovarian cancer.¹

HRD=homologous recombination deficiency.

1. Lynparza (olaparib). Summary of Product Characteristics. July 2025.

This promotional material has been fully funded and developed by AstraZeneca and MSD

For UK healthcare professionals only.

Click here for UK Prescribing Information.

GB-68473 | November 2025

or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033

Lynparza tablets are indicated in combination with bevacizumab for the maintenance treatment of patients with advanced HRD-positive ovarian cancer.²

ESGO=European Society of Gynaecological Oncology; ESMO=European Society for Medical Oncology; ESP=European Society of Pathology; HRD=homologous recombination deficiency.

1. Ledermann J, et al. Ann Oncol. 2024;35:248–266; 2. Lynparza (olaparib). Summary of Product Characteristics. July 2025.

For UK healthcare professionals only. Adverse event reporting can be found on the first frame of this banner.

Click here for UK Prescribing Information.

GB-68473 | November 2025